Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15031
UPID:
SYLM_HUMAN
Alternative names:
Leucyl-tRNA synthetase
Alternative UPACC:
Q15031
Background:
Leucine--tRNA ligase, mitochondrial, also known as Leucyl-tRNA synthetase, plays a crucial role in protein synthesis by catalyzing the attachment of leucine to its cognate tRNA. This enzyme is essential for the translation of genetic information into functional proteins.
Therapeutic significance:
Leucine--tRNA ligase, mitochondrial, is implicated in Perrault syndrome 4, characterized by sensorineural deafness and ovarian dysgenesis, and in a metabolic disorder leading to severe lactic acidosis and sideroblastic anemia. Understanding the role of Leucine--tRNA ligase could open doors to potential therapeutic strategies for these conditions.